Moving Beyond Truvada for PrEP: The Next Generation of Biomedical HIV Prevention and What It Means for Los Angeles
Date(s) - Jul 14, 2016
9:30 AM - 10:45 AM
Truvada, used as PrEP is highly effective for preventing HIV in diverse populations and risk groups when taken daily as prescribed. Some individuals find it challenging to adhere to a daily medication; less than daily use may compromise protective efficacy. The next generation of PrEP agents will attempt to improve on the effectiveness, safety, tolerability, and acceptability of Truvada. Two new NIH-sponsored multi-site clinical trials (HPTN 085 and 083) designed to help develop new PrEP agents and strategies for prevention will have participating sites in Los Angeles. These studies are an opportunity for at-risk MSM and transgender individuals who have sex with men to be a part of cutting-edge scientific research. HPTN 085 evaluates the safety of the broadly neutralizing antibody VRC01 as an intravenous infusion for HIV prevention; HPTN 083 compares daily oral Truvada to a long acting injectable antiretroviral (cabotegravir) for HIV prevention. Both studies will contribute critically important information to move the field of biomedical HIV prevention forward, and in the process bring new HIV prevention strategies to the most at-risk populations of Los Angeles County.